SARSYS AB reported a slight increase in Q1 2025 sales but a wider loss, with order intake plunging and gross margin falling sharply. A rights issue improved liquidity, but negative equity and ongoing subsidiary reconstruction highlight continued financial risk.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.